Preventive effect of taurine on experimental type II diabetic nephropathy

Journal of Biomedical Science

Volumn 17, Issue SUPPL. 1, 2010, Pages

  Lin, Shumei ^a   Yang, Jiancheng ^a   Wu, Gaofeng ^a   Liu, Mei ^a   Luan, Xinhong ^a   Lv, Qiufeng ^a   Zhao, He ^a  

^a SHENYANG AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMININ 1; LAMININ B1; PROTECTIVE AGENT; TAURINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GLOMERULUS BASEMENT MEMBRANE; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INSULIN RESISTANCE; KIDNEY FUNCTION; LIPID METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; ANIMAL; ARTICLE; DIET; HUMAN; KIDNEY; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZATION; WISTAR RAT;

RATTUS;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIET; GLOMERULAR BASEMENT MEMBRANE; HUMANS; KIDNEY; LIPID METABOLISM; MALE; RANDOM ALLOCATION; RATS; RATS, WISTAR; STREPTOZOCIN; TAURINE;

EID: 77956039510     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-17-S1-S46     Document Type: Conference Paper

References (30)

1. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study. AR Andersen JS Christiansen JK Andersen S Kreiner T Deckert, Diabetologia 1983 25 6 496 501 10.1007/BF00284458 6363177
2. Declining Incidence of Nephropathy in Insulin-Dependent Diabetes Mellitus. B Mats JA Hans H Goran EK Bengt L Johnny, N Engl J Med 1994 330 1 15 18 10.1056/NEJM199401063300103 8259139
3. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. MB Barry EC Mark Z Dick de FK William EM William P Hans-Henrik R Giuseppe MS Steven Z Zhonxin S Shahnaz, N Engl J Med 2001 345 12 861 869 10.1056/NEJMoa011161 11565518
4. Pathogenesis of diabetic nephropathy. W Zirun, Modem Journal of Integrated Traditional Chinese and Western Medicine 2009 18 19 2349 2350
5. Effect of taurine on alcoholic liver disease in rats. W Gaofeng Y Jiancheng S Changmian L Xinhong S Jiao H Jianmin, Amino Acids 2009 36 457 464 10.1007/s00726-008-0101-2 18509591
6. Taurine ameliorates chronic streptozocin-induced diabetic nephropathy in rats. H Trachtman S Futterweit J Maesaka C Ma E Valderrama A Fuchs A A Tarectecan PS Rao JA Sturman TH Boles,, et al. Am J Physiol 1995 269 3 Pt 2 429 F438 7573492
7. The protective effect of taurine against gentamicin-induced acute tubular necrosis in rats. A Erdem NU Gundogan A Usubutun K Kilinc SR Erdem A Kara A Bozkurt, Nephrol. Dial. Transplant 2000 15 8 1175 1182 10.1093/ndt/15.8.1175 10910441
8. Taurine Administration after Appearance of Proteinuria Retards Progression of Diabetic Nephropathy in Rats. S Higo S Miyata QY Jiang, Kobe J. Med. Sci 2008 54 1 35 E45 18772607
9. Melatonin and taurine reduce early glomerulopathy in diabetic rats. H Ha MR Yu KH Kim, Free Radic Biol Med 1999 26 4 944 950 10.1016/S0891-5849(98)00276- 7 10232838
10. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. EY Skolnik Z Yang Z Makita S Radoff M Kirstein H Vlassara, J Exp Med 1991 174 4 931 939 10.1084/jem.174.4.931 1655949
11. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. M Emoto Y Nishizawa K Maekawa Y Hiura H Kanda T Kawagishi T Shoji Y Okuno H Morii, Diabetes care 1999 22 5 818 822 10.2337/diacare.22.5.818 10332688
12. The effect of intensive treatment of diabetes on the development and progression of long-term complications in the insulin-dependent diabetes mellitus. DCCT Research Group, N EngI J Med 1993 329 977 986 10.1056/NEJM199309303291401
13. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UKPDS Group, Lancet 1998 352 837 853 10.1016/S0140-6736(98) 07019-6 9742976
14. Protective actions of taurine against streptozotocin-induced hyperglycemia. H Tokunaga Y Yoneda K Kuriyama, Biochem Pharmacol 1979 28 18 2807 2811 10.1016/0006-2952(79)90566-5 159055
15. Supplemental taurine in diabetic rats:effects on plasma glucose and triglycerides. OG Harold KS Zak, Biochem Med Metab Biol 1990 43 1 1 9 10.1016/0885-4505(90)90002-I 2310608
16. Influence exerted by taurine on the utilization of glucose by the rat. G Donadio P Fromageot, Bull Soc Chim Biol (Paris) 1964 46 293 302 14165545
17. The Zucker rat model of obesity, insulin resistance, hyperlipidemia and renal injury. BL Kasiske MP ODonnel, Hypertension 1992 19 1 Suppl 110 I115 1730447
18. Effect of Taurine on Experimental HyperIipidemia in Rats. J Lin Y Kang, Chinese Journal of Hypertension 1998 6 1 14 16
19. Effect of Natural Taurine on Reducing Blood Lipids. Z Peng L Bin Y Junfeng L Rongzhen H Weitao L Fengwen, Acta Nutrimenta Sinica 2005 27 1 70 71
20. Hypolipidemic Effect of Taurine in Stroke-Prone Spontaneously Hypertensive Rats. S Murakami I Yamagishi Y Asami Y Ohta Y Toda Y Nara Y Yamori, Pharmacology 1996 52 5 303 313 10.1159/000139395 8807674
21. The changes of the serum level of the type IV collagen as well as laminin in diabetic nephropathies and its correlated risk factors. X Meilun L Weifang W Weiqiong, HaiNan Med J 2007 16 2 6 7
22. Selective proteinuria in diabetic nephropathy in the rat is associated with a relative decrease in glomerular basement membrane heparan sulphate. J Born AA Kraats MAH Bakker KJM Assmann LPWJ Heuvel JH Veerkamp JHM Berden, Diabetologia 1995 38 2 161 172 10.1007/BF00400090 7713310
23. Laminin - a glycoprotein from basement membrane. R Timpl H Rohde PG Robey SI Rennard JM Foidart GR Martin, The Journal of Biological Chemistry 1979 254 10 9933 9937 114518
24. The Laminin B2 Chain Has Multidomain Structure Homologous to the B1 Chain. M Sasaki Y Yamada, The Journal of Biological Chemistry 1987 262 15 17111 17117 3680290
25. Shapes, domain organizations and flexibility of laminin and fibronectin, two multifunctional proteins of the extracellular matrix. J Engel E Odermatt A Engel JA Madri H Furthmayr H Rohde R Timpl, J. Mol. Biol 1981 150 25 97 120 10.1016/0022-2836(81)90326-0 6795355
26. Evidence for coiled-coil alpha-helical regions in the long arm of laminin. M Paulsson R Deutzmann R Timpl D Dalzoppo E Odermatt J Engel, EMBO J 1985 4 2 309 316 3848400
27. Collagen IV is essential for basement membrane stability but dispensable for initiation of its assembly during early development. E Poschl U Schlotzer-Schrehardt B Brachvogel K Saito Y Ninomiya U Mayer, Development 2004 131 4 1619 1628 10.1242/dev.01037 14998921
28. Attenuation of Extracellular Matrix Accumulation in Diabetic Nephropathy by the Advanced Glycation End Product Cross-Link Breaker ALT-711 via a Protein Kinase C-Dependent Pathway. V Thallas-Bonke C Lindschau B Rizkalla LA Bach V Thallas-Bonke C Lindschau B Rizkalla LA Bach G Boner M Meier H Haller ME Cooper JM Forbes, Diabetes 2004 53 11 2921 2930 10.2337/diabetes.53.11.2921 15504973
29. ECM gene expression and its modulation by insulin in diabetic rats. M Fukui T Nakamura I Ebihara I Shirato Y Tomino H Koide, Diabetes 1992 41 12 1520 1527 10.2337/diabetes.41.12.1520 1280237
30. Overexpression of transforming growth factor-beta 1 mRNA is associated with up-regulation of glomerular tenascin and laminin gene expression in nonobese diabetic mice. CW Yang M Hattori H Vlassara CJ He MA Carome E Yamato S Elliot GE Striker LJ Striker, Journal of the American Society of Nephrology 1995 5 8 1610 1617 7538809